Novartis Makes Plans For Its Cancer-Killing T Cells – Forbes
Forbes |
Novartis Makes Plans For Its Cancer-Killing T Cells
Forbes There's a race on to be the first company to launch what's a CAR-T — a technology that genetically alters cancer patients' white blood cells to kill tumor cells. (It stands for chimeric antigen receptor T–cell, which means "white blood cells with … Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority Review First come, first served: Novartis finalizes CAR–T application, claims priority review Does the drama of the CAR–T race actually matter? |
